These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11147506)

  • 1. Levodopa in the treatment of Parkinson's disease.
    Koller WC
    Neurology; 2000; 55(11 Suppl 4):S2-7; discussion S8-12. PubMed ID: 11147506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complications and limitations of drug therapy for Parkinson's disease.
    Jankovic J
    Neurology; 2000; 55(12 Suppl 6):S2-6. PubMed ID: 11188970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa: past, present, and future.
    Hauser RA
    Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa in the treatment of Parkinson's disease.
    Lloyd KG
    Prim Care; 1977 Sep; 4(3):541-60. PubMed ID: 264229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution and origin of motor complications in Parkinson's disease.
    Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.